Cargando…

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin

Detalles Bibliográficos
Autores principales:	Liang, Sixian, Peng, Xun, Li, Xiaoli, Yang, Ping, Xie, Linhao, Li, Yaochen, Du, Caiwen, Zhang, Guojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979100/ https://www.ncbi.nlm.nih.gov/pubmed/35391718 http://dx.doi.org/10.18632/oncotarget.28109

Ejemplares similares

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Author Correction: Quantitative proteomic analysis of enhanced cellular effects of electrochemotherapy with Cisplatin in triple-negative breast cancer cells
por: Mittal, Lakshya, et al.
Publicado: (2019)

Correction: NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin
por: Lin, Chao, et al.
Publicado: (2012)

Author Correction: Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature
por: Li, Jia-wei, et al.
Publicado: (2020)

Correction: EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer
por: Wang, Xuemin, et al.
Publicado: (2015)

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Correction: WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
por: Ertay, Ayse, et al.
Publicado: (2021)

Correction: EPS8 Inhibition Increases Cisplatin Sensitivity in Lung Cancer Cells
Publicado: (2014)

Correction: Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
por: Shao, Fuqiang, et al.
Publicado: (2023)

Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2011)

Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Correction: GPR110 promotes progression and metastasis of triple-negative breast cancer
por: Nam, Hye-Jung, et al.
Publicado: (2022)

Correction: CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12
Publicado: (2014)

Correction: circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/CXCR4 signaling
por: Zheng, Xun, et al.
Publicado: (2023)

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
por: Goldstein, Lori J., et al.
Publicado: (2020)

Correction for: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma
por: Zi, Dan, et al.
Publicado: (2022)

Correction for: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma
por: Zi, Dan, et al.
Publicado: (2023)

Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Correction: Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy
por: Li, Heng, et al.
Publicado: (2022)

Correction to: ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma
por: Peng, Hao, et al.
Publicado: (2022)

Correction: Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
por: Chapman, Margaret P., et al.
Publicado: (2019)

Correction for: A novel fatty-acid metabolism-based classification for triple negative breast cancer
por: Yang, Xia, et al.
Publicado: (2023)

Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells
por: Yang, Meng, et al.
Publicado: (2019)

Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
por: Mann, Minakshi, et al.
Publicado: (2019)

Correction: Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway
por: Wei, Fangyuan, et al.
Publicado: (2013)

Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021)

Correction to: Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity
por: Qin, Tao, et al.
Publicado: (2021)

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
por: de Heer, E. C., et al.
Publicado: (2023)

Correction to: A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients
por: Sun, Chaoyang, et al.
Publicado: (2020)

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells
por: Zhang, Yang, et al.
Publicado: (2018)

Silencing CTNND1 Mediates Triple-Negative Breast Cancer Bone Metastasis via Upregulating CXCR4/CXCL12 Axis and Neutrophils Infiltration in Bone
por: Lin, Qun, et al.
Publicado: (2021)

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer
por: Wang, Yuyi, et al.
Publicado: (2018)

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin
por: Li, Weijia, et al.
Publicado: (2023)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Correction: Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype
Publicado: (2014)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gr6prl73ieij6lc2ddjn6neb4k